AF-CARE Framework
Definition
AF-CARE is the structured management framework introduced in the 2024 ESC Guidelines for atrial fibrillation, replacing the 2020 ABC (Anticoagulation, Better symptom management, Cardiovascular risk factor management) pathway. It consists of four sequential but interconnected pillars applied to all patients with AF: [C] Comorbidity and risk factor management, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, and [E] Evaluation and dynamic reassessment.
Key Concepts
[C] Comorbidity and Risk Factor Management
- Placed as the first and most critical pillar, applicable to all AF patients before considering anticoagulation or rate/rhythm control (sources/AF-ESC-2024, rating: very high)
- Key targets: hypertension (BP-lowering Class I/B), heart failure (SGLT2 inhibitors Class I/A regardless of EF), diabetes (effective glycaemic control Class I/C), obesity (≥10% weight loss Class I/B), obstructive sleep apnoea (IIb/B), physical inactivity (tailored exercise Class I/B), alcohol excess (≤3 drinks/week Class I/B) (sources/AF-ESC-2024)
- The rationale is that untreated comorbidities drive AF recurrence, reduce efficacy of rate/rhythm control, and worsen outcomes (sources/AF-ESC-2024)
- SGLT2 inhibitors are the first Class I/A recommendation for AF patients with HF of any ejection fraction; reduce HF hospitalisation and CV death (sources/AF-ESC-2024)
[A] Avoid Stroke and Thromboembolism
- Uses the CHA2DS2-VA score (sex category removed from CHA2DS2-VASc): OAC recommended if score ≥2; should be considered if score = 1 (sources/AF-ESC-2024)
- DOACs preferred over VKAs (Class I/A) except in mechanical heart valves or moderate-to-severe mitral stenosis (sources/AF-ESC-2024)
- Temporal AF pattern (paroxysmal vs. persistent vs. permanent) is irrelevant to OAC decision-making (sources/AF-ESC-2024)
- Antiplatelet therapy alone is not an alternative to OAC and should not be combined with OAC to prevent stroke (Class III/B) (sources/AF-ESC-2024)
- Modifiable bleeding risk factors should be addressed; bleeding risk scores should not be used to withhold OAC (Class III/B) (sources/AF-ESC-2024)
- Surgical LAA closure during cardiac surgery recommended as adjunct to OAC (Class I/B — LAAOS III trial) (sources/AF-ESC-2024)
[R] Reduce Symptoms by Rate and Rhythm Control
- Rate control: Lenient target HR <110 bpm; beta-blockers, digoxin, diltiazem/verapamil (LVEF >40%); beta-blockers or digoxin only if LVEF ≤40% (sources/AF-ESC-2024)
- Rhythm control: Should be explicitly discussed with all suitable AF patients; primary indication is symptom reduction; selected patients (HFrEF, early AF, elevated thromboembolic risk) may also benefit prognostically (sources/AF-ESC-2024)
- Catheter ablation: Class I/A as first-line for paroxysmal AF (major upgrade from 2020); Class I/B for persistent AF with failed AAD (sources/AF-ESC-2024)
- Early rhythm control (within 12 months of diagnosis) should be considered in patients at thromboembolic risk (Class IIa/B — EAST-AFNET 4 trial) (sources/AF-ESC-2024)
- Four patient-specific [R] pathways exist for: first-diagnosed, paroxysmal, persistent, and permanent AF (sources/AF-ESC-2024)
[E] Evaluation and Dynamic Reassessment
- Re-evaluate 6 months after initial presentation, then at least annually or per clinical need (sources/AF-ESC-2024)
- Assessment includes: ECG, blood tests (renal/liver/thyroid/HbA1c), symptom evaluation, thromboembolism risk, cardiac imaging as needed (sources/AF-ESC-2024)
- OAC continuation is decided by stroke risk irrespective of whether patient is in AF or sinus rhythm — even after successful ablation (Class I) (sources/AF-ESC-2024)
- TTE valuable across all AF-CARE domains; evaluate LV function, valvular disease, LA size, for management decisions (sources/AF-ESC-2024)
- Patient-reported outcome measures (PROMs: AFEQT, AFSS) should be used to guide treatment decisions (sources/AF-ESC-2024)
Contradictions / Open Questions
- Optimal timing and components of dynamic reassessment are not standardized; RACE 4 trial failed to show superiority of nurse-led over usual care for integrated AF management (sources/AF-ESC-2024)
- Whether anticoagulation can be safely stopped after successful catheter ablation is unresolved; current evidence does not support discontinuation based on rhythm outcome alone (sources/AF-ESC-2024)
- The definition of 30 seconds for clinical AF on ambulatory monitoring lacks validation against clinical outcomes (sources/AF-ESC-2024)
Connections
- Related to entities/Atrial-Fibrillation
- Related to concepts/CHA2DS2-VA
- Related to concepts/Catheter-Ablation-AF
- Related to entities/Atrial-Flutter